Joint Formulary & PAD

White Birch pollen allergen extract - Allergic rhinitis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral lyophilisates
Associated Icons :
Restrictions / Comments :
Important

BLUE for ADULTS only. 

To be initiated by Specialist Immunology only. Specialist to retain prescribing responsibility for at least 3 months before making any request to transfer prescribing to primary care.

Maximum of 3 years course only (SPC), clear instruction for how to stop to be in clinic letter.

An information sheet has been developed to support prescribers in the arrangements for shared care (see below).

Documents :
 
 

Status 2

Red
Formulations :
  • Oral lyophilisates
Associated Icons :
Restrictions / Comments :
Important

RED for ages 5 to 18 years only.

Specialist immunology only

PAD Profile

ChemicalSubstance :
White Birch pollen allergen extract
Indication :
Allergic rhinitis
Group Name :
Keywords :
allergic disorders, allergens, allergen therapy, hyposensitising agents, tree pollen allergy, allergic conjunctivitis, Betula verrucosa
Brand Names Include :
Itulazax
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3
Traffic Light Entries :
2

Committee Recommendations (3)

The Surrey & Sussex Integrated Care Board Area PrescribingCommittee (APC) approved the betula verrucosa (Itulazax®) information sheet for clinicians and its host on both Surrey and Sussex formularies. 

BLUE (with specialist team initiation) traffic light status has been agreed with at least 3 months prescribing by the specialist team to enable a review and confirmation of clinical benefit, prior to any request to transfer prescribing responsibility to Primary Care.

The Surrey Heartlands Integrated Care System Area Prescribing Committee assigned a RED traffic light status for the treatment of allergic rhinitis or conjunctivitis in patients under the age of 18 years, whilst awaiting a NICE Technology Appraisal  in Summer 2026.

03 Oct 25 - RSFT DTC

Previously approved for adults. now approved for over 5 years